NASDAQ:EXEL
Exelixis Stock News
$23.53
-0.180 (-0.759%)
At Close: Apr 25, 2024
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
04:05pm, Thursday, 10'th Nov 2022
ALAMEDA, Calif.--( BUSINESS WIRE )--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will participate in fireside chats at the following investor conferences
Here's Why This Growth Stock Is Already My 2022 Winner
02:53pm, Wednesday, 09'th Nov 2022 The Motley Fool
Despite a challenging year for the markets, this growth stock managed to stand out with another stellar quarter.
Here's Why This Growth Stock Is Already My 2022 Winner
09:53am, Wednesday, 09'th Nov 2022
Despite a challenging year for the markets, this growth stock managed to stand out with another stellar quarter.
Exelixis: Undervalued And Unloved
07:08am, Monday, 07'th Nov 2022
Today, we circle back on mid-cap oncology concern Exelixis, Inc. which just delivered another quarter of rock-solid results. Its blockbuster drug CABOMETYX continues to show good growth and the compan
What 4 Analyst Ratings Have To Say About Exelixis
07:16pm, Wednesday, 02'nd Nov 2022 Benzinga
Exelixis (NASDAQ:EXEL) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
2
1
0
0
Last 30D
0
1
Exelixis (EXEL) Q3 Earnings & Sales Top, Cabometyx Aids Growth
03:23pm, Wednesday, 02'nd Nov 2022 Zacks Investment Research
Exelixis (EXEL) tops earnings and sales estimates for the third quarter as demand for its lead drug, Cabometyx, remains strong.
Exelixis (EXEL) Q3 Earnings & Sales Top, Cabometyx Aids Growth
12:48pm, Wednesday, 02'nd Nov 2022
Exelixis (EXEL) tops earnings and sales estimates for the third quarter as demand for its lead drug, Cabometyx, remains strong.
Exelixis (EXEL) Q3 2022 Earnings Call Transcript
05:30am, Wednesday, 02'nd Nov 2022 The Motley Fool
EXEL earnings call for the period ending September 30, 2022.
Exelixis, Inc. (EXEL) Q3 2022 Earnings Call Transcript
08:50pm, Tuesday, 01'st Nov 2022
Exelixis, Inc. (NASDAQ:EXEL ) Q3 2022 Earnings Conference Call November 1, 2022 5:00 PM ET Company Participants Susan Hubbard – Executive Vice President of Public Affairs and Investor Relations Mike
Exelixis (EXEL) Beats Q3 Earnings and Revenue Estimates
06:49pm, Tuesday, 01'st Nov 2022
Exelixis (EXEL) delivered earnings and revenue surprises of 24% and 1.88%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
02:27pm, Tuesday, 01'st Nov 2022 Benzinga
Upgrades
For AnaptysBio Inc (NASDAQ:ANAB), Guggenheim upgraded the previous rating of Neutral to Buy. AnaptysBio earned $1.15 in the second quarter, compared to $0.02 in the year-ago quarter. The sto
Drug/Biotech Stocks' Q3 Earnings on Nov 1: PFE, LLY & More
08:07pm, Monday, 31'st Oct 2022 Zacks Investment Research
Let's analyze how the five pharma/drug/biotech companies are placed before the quarterly earnings release on Nov 1.
Nasdaq Bear Market: 5 Magnificent Growth Stocks You'll Regret Not Buying on the Dip
09:06am, Saturday, 29'th Oct 2022 The Motley Fool
With the Nasdaq Composite down as much as 38% from its peak, these highly innovative companies are ripe for the picking.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
01:40pm, Friday, 28'th Oct 2022 Zacks Investment Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
2 Top Biotech Stocks to Buy for the Long Haul
12:15pm, Friday, 28'th Oct 2022 The Motley Fool
Both drugmakers have outperformed the market in the past year.
